IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

Autor: Mallardo D; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Simeone E; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Festino L; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Tuffanelli M; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Vanella V; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Trojaniello C; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Vitale MG; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Ottaviano M; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Capone M; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Madonna G; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Sparano F; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Cioli E; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Scarpato L; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Palla M; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Di Trolio R; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Meinardi P; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Caracò C; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Ferrara G; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Muto P; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Cavalcanti E; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy., Ascierto PA; Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Naples, Italy. p.ascierto@istitutotumori.na.it.
Jazyk: angličtina
Zdroj: Journal of translational medicine [J Transl Med] 2023 Feb 23; Vol. 21 (1), pp. 140. Date of Electronic Publication: 2023 Feb 23.
DOI: 10.1186/s12967-023-03971-5
Abstrakt: Background: Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment.
Methods: Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study.
Results: Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy.
Conclusions: Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje